Key Highlights

  • Revenue rose 10% on an FX-neutral basis and 19% as reported, to S/1,325 million.
  • Adjusted EBITDA was S/231 million, down 4.6% on an FX-neutral basis and flat as reported.
  • Mexico segment Adjusted EBITDA increased 5% in local currency, the first year-over-year growth for the segment in 2026.
  • Leverage improved to 3.5x, and year-to-date free Cash Flow increased 95% to S/626 million.

Auna (NYSE:AUNA), a healthcare platform with operations in Mexico, Peru and Colombia, reported unaudited results for the third quarter ended September 30, 2026. Results are expressed in Peruvian soles and prepared under International Financial Reporting Standards. Revenue increased 10% on an FX-neutral basis and 19% as reported, to S/1,325 million.

Adjusted EBITDA was S/231 million, down 4.6% on an FX-neutral basis and flat as reported. The Adjusted EBITDA Margin was 17.5%, compared with 18.4% in the second quarter of 2026. The company attributed the decline mainly to profitability pressure in Colombia and Peru.

Country Performance

In Peru, revenue increased 6% year over year. The Peru Healthcare network posted surgical volumes up 21%, and the Oncosalud Business added two business-to-business agreements expected to onboard 4,000 members. Peru Adjusted EBITDA was affected by penalties from reconciling prior years’ receivables and by higher pharmacy and clinical Payroll costs tied to patient volumes.

In Mexico, Segment Adjusted EBITDA increased 5% in local currency, the first year-over-year increase for the segment in 2026. The company credited the Monterrey Healthcare network, where surgical and oncology volumes and capacity utilization improved, and said oncology revenue grew at a double-digit rate. Auna Seguros results were softer after changes in VAT deductibility.

Colombia Pressures and Operating Metrics

In Colombia, revenue increased 12% in local currency, supported by added hospital capacity in Montería and growth in PGP arrangements. Segment Adjusted EBITDA declined 30% in local currency. The company cited extraordinary medical costs under a specific oncology risk-sharing contract, where treatment costs exceeded contractual assumptions, together with regulatory price caps on certain high-cost oncology medicines and higher personnel costs.

Auna terminated the risk-sharing contract, which represented about 4% of Colombia’s revenue, to limit further exposure. Operating volumes rose across the group, with surgeries up 12% to 23,932, hospital days up 6% to 144,041 and chemotherapy and radiotherapy sessions up 7%. Oncology medical loss ratio was stable at 50.7%.

Cash Generation and Leverage

Year-to-date net cash from Operating Activities increased 62% to S/713 million, and free cash flow rose 95% to S/626 million. Its Leverage ratio improved to 3.5x over the same period.

Auna’s executive chairman and president said the quarter reflected continued commercial momentum, with a milestone in Mexico’s operational recovery. The company did not provide quarterly guidance for the coming period in the release.

Final Word

Auna grew revenue by 10% on an FX-neutral basis in the third quarter, while profitability was held back by Colombia and Peru. Mexico’s return to growth and the improved Leverage Ratio are the release’s main operating markers.

Adjusted EBITDA margin contracted to 17.5%, and the Colombian contract termination limits one source of cost pressure going forward. Results for the fourth quarter will show whether the Mexico recovery holds and whether Peru’s margin pressure eases.